Macular Degeneration Fact Sheet

Blindness Fact Sheet

CIRM funds several research projects working to understand the basic mechanisms of macular degeneration and to develop novel stem cell-based therapies for the disease.

If you want to learn more about CIRM funding decisions or make a comment directly to our board, join us at a public meeting. You can find agendas for upcoming public meetings on our meetings page.

Learn more about stem cell research:
Stem Cell Basics Primer | Stem Cell Videos | What We Fund

Find clinical trials:
CIRM does not track stem cell clinical trials. If you or a family member is interested in participating in a clinical trial, please see the national trial database to find a trial near you: clinicaltrials.gov

The role of stem cells in blindness

Nearly a million Americans are blind, with another 2.4 million suffering significant visual impairment. While there are several causes of blindness, the leading cause of all visual impairment is age-related macular degeneration, which affects 1.7 million Americans. 

California’s stem cell agency funds research into potential therapies for three of the causes of blindness. All the research teams are seeking to use various forms of stem cells to rescue or replace cells in the eye damaged or threatened by the diseases. Several groups are working on ways to restore vision for people with age-related macular degeneration (AMD). Other projects are looking to preserve vision in patients with retinitis pigmentosa, and to restore clarity to the surface of eyes impacted by corneal disease.

Macular degeneration

In AMD the layer of cells that support the photoreceptors is destroyed. Without this support system, the photoreceptors, the cells that actually allow us to sense light start to malfunction. CIRM-funded teams are looking at various methods of replacing this layer of support cells called RPE (retinal pigment epithelial) cells. Some are using embryonic stem cells as a starting point to generate new RPE cells. Others are using stem cells obtained by reprogramming adult cells to be like embryonic cells, which could potentially come from the patients’ themselves.

Retinitis pigmentosa

Retinitis pigmentosa, an inherited and progressive vision loss that leaves most patients legally blind by mid-life, directly destroys the photoreceptors. CIRM-funded researchers are seeking to use stem cells to rescue the receptors from further damage and potentially replace them with new ones.

limbal stem cell deficiency

The cornea, the outer surface of the eye, is constantly refreshed by stem cells that reside in neighboring tissue. But some people just don’t have enough of these stem cells, called Limbal stem cells, to make enough new cornea cells. CIRM-funded researcher are trying to correct this condition, limbal stem cell deficiency, by retrieving the few existing limbal stem cells, and using various techniques to expand them in the laboratory until there are enough cells to rebuild a healthy cornea.

Some projects we fund are trying to take promising therapies out of the laboratory and closer to being tested in people. These Disease Team Awards encourage the creation of teams that have both the scientific knowledge and business skills needed to produce therapies that can get approval from the Food and Drug Administration (FDA) to be tested in people. In some cases, these awards also fund the early phase clinical trials to show that they are safe to use and, in some cases, show some signs of being effective.

Disease team awards

University of Southern California

This team proposes to use embryonic stem cells to produce the support cells, or RPE cells, needed to replace those lost in age-related macular degeneration. Because these cells exist in a thin sheet in the back of the eye, they are assembling these sheets in the lab by growing the RPE cells on synthetic scaffolds. These sheets would be surgically implanted into the eye. They plan to complete all pre-clinical testing to gain FDA approval to begin a clinical trial.

University of California, Irvine

For retinitis pigmentosa the team plans to use donor tissue to isolate cells that are part way down the path from neural stem cells to adult eye tissue. These retinal progenitor cells would be grown in large quantities in the lab and then injected into the eye. The team suggests the cells could help in two ways. They may be able to protect the photoreceptors not yet damaged by the disease, and they may be able to form new photoreceptors to replace those already lost. They plan to complete testing needed to apply to the FDA to begin a trial and to complete an early phase trial of the therapy.


Mark Humayun, who leads the USC disease team, discusses his approach to treating macular degeneration

CIRM Grants Targeting Vision Loss

Researcher name Institution Grant Title Approved funds
Henry Klassen University of California, Irvine Human retinal progenitor cells as candidate therapy for retinitis pigmentosa $1,803,768
Deepak Lamba Buck Institute for Age Research 3D Modeling of Retina using Polymer Scaffolds for Understanding Disease Pathogenesis $1,212,553
Sophie Deng University of California, Los Angeles Regeneration of Functional Human Corneal Epithelial Progenitor Cells $2,224,930
David Hinton University of Southern California Therapeutic potential of Retinal Pigment Epithelial cell lines derived from hES cells for retinal degeneration. $651,607
Martin Friedlander Scripps Research Institute Autologous Retinal Pigmented Epithelial Cells Derived from Induced Pluripotent Stem Cells for the Treatment of Atrophic Age Related Macular Degeneration $5,866,528
Gabriel Travis University of California, Los Angeles Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration $5,487,136
Mark Humayun University of Southern California Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) $18,904,916
Peter Coffey University of California, Santa Barbara Development of Cellular Therapies for Retinal Disease $4,850,116
Henry Klassen University of California, Irvine Retinal progenitor cells for treatment of retinitis pigmentosa $17,144,825
Mark Humayun University of Southern California Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Parylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration $18,922,665
Thomas Novak Cellular Dynamics International Generation and characterization of high-quality, footprint-free human induced pluripotent stem cell lines from 3,000 donors to investigate multigenic diseases $16,000,000
Steven Madore Coriell Institute for Medical Research The CIRM Human Pluripotent Stem Cell Biorepository – A Resource for Safe Storage and Distribution of High Quality iPSCs $9,942,175
Kang Zhang University of California, San Diego Generation of fibroblast cell lines in patients with common blinding eye diseases $1,034,425
Magdalene Seiler University of California, Irvine Restoring vision by sheet transplants of retinal progenitors and retinal pigment epithelium (RPE) derived from human embryonic stem cells (hESCs) $3,998,948
Total:
$108,044,592.00

CIRM Macular Degeneration Videos

News and Information

Resources

 

© 2013 California Institute for Regenerative Medicine